Peroxisome proliferators are believed to induce liver tumors in rodents due to sustained increase in cell proliferation and oxidative stress resulting from the induction of peroxisomal enzymes. The objective of this study was to conduct a sequential analysis of the early changes in cell-cycle kinetics and the dynamics of rat liver DNA synthesis after treatment with a peroxisome proliferator. Immunofluorescent detection of proliferating cell nuclear antigen (PCNA) and bromodeoxyuridine (BrdU) incorporation into DNA during S phase were used to assess rat hepatocyte proliferation in vivo during dietary administration of Wy-14,643, a known peroxisome proliferator and hepatocarcinogen in rodents. Rats were placed on a diet containing 0.1% Wy-14,643 and implanted subcutaneously with 5-bromo-2'-deoxyuridine containing osmotic pumps 4 days prior to being sacrificed on days 4, 11, and 25 of treatment. Isolated liver nuclei labeled with fluorscein isothiocyanate (FITC)-anti-BrdU/PI and FITC-anti-PCNA/PI were analyzed for S-phase kinetics using flow cytometry. Morphometric analysis was performed to evaluate nuclear and cell size and enumeration of BrdU labeled cells, binucleated hepatocytes, and mitotic index. The BrdU labeling index increased 2-fold in livers of Wy-14,643-treated rats at day 4, but distribution of cells in G 1 , S phase, and G 2 -M did not differ significantly from controls. PCNA-positive cells decreased from 36% on day 4 to 17% on day 25, whereas the percentage of PCNA-positive cells in controls increased 2-fold from day 4 to day 11 and remained unchanged up to day 25. The differences in the number of PCNA-positive nuclei between control and Wy-14,643-treated groups were statistically significant only on day 4. Binucleated hepatocytes, determined by morphometric analysis, increased slightly on day 25 in treated rats parallel to an increase in the percentage of cells in G 2 -M phase. Significant shifts were noted in nuclear diameter and nuclear area after 11 and 25 days of treatment with Wy-14,643. Hepatic cell populations with nuclei >9 &mu;m diameter and nuclear area >64 &mu;m 2 increased in Wy-14,643-fed rats during the treatment period compared with the control, indicating hepatic karyomegaly and hyperploidy, whereas percentage of distribution of nuclei based on diameter and area remained consistently unchanged in control animals from 4 through 25 days of sham treatment. The flow cytometric and morphometric analysis indicated an initial wave of DNA synthesis in response to Wy-14,643. The hepatomegaly was sustained over the treatment period accompanied by increase in ploidy with a significant shift toward hyperploidic hepatocytes. The increase in DNA content was almost entirely accounted for by the overall polyploidy increase rather than by an absolute increase in cells.
INTRODUCTION
Cell proliferation is a critical step in the initiation and promotion stages of chemically induced hepatocarcinogenesis (6, 31, 32, 34, 42, 44) . Peroxisome proliferators, such as hypolipidemic compounds and phthalate ester plasticizers, cause liver tumors in rodents when chronically fed in diet (31, 37, 39) . The early pleiotropic responses induced by peroxisome proliferators have been extensively characterized and the mechanism by which peroxisome proliferators induce liver tumors appears to be related to sustained increases in cell proliferation or to oxidative stress resulting from excess hydroxyperoxides formed following peroxisomal enzyme induction (1, 10, 20, 37, 39) . Liver enlargement after peroxisome proliferator administration to rats, mice, and hamsters has been shown to be a response consisting of cellular hy-pertrophy and hyperplasia (1, 37, 39) . Although nonmutagenic, peroxisome proliferators characteristically induce an initial wave of DNA synthesis in liver, indicative of cell proliferation.
Hepatocyte growth patterns obtained from flow cytometric analysis of DNA distribution are advantageous because a large number of cells can be evaluated with increased sensitivity for the incorporation of precursors, such as bromodeoxyuridine (BrdU), a thymidine analog (19, 43) . Studies of cell proliferation utilizing BrdU incorporation have shown that the technique is applicable to hepatocytes (17, 19, 26, 43, 49) . The flow cytometric characterization of cell proliferation represents total liver mass, and the responses could be diluted if the effects are restricted to lobular disposition. In addition, immunohistochemical methods for detecting BrdU incorporation into DNA of proliferating cells make it possible to investigate liver cell proliferation in terms of lobular pattern determination.
The objective of this study was to conduct a sequential analysis of the early changes in liver cell cycle kinetics and the dynamics of DNA synthesis in rat liver after treatment with a peroxisome proliferator. Changes in DNA synthesis were evaluated by implanting BrdU pumps in rats fed Wy-14,643 designated as [4-chloro-6- (2,3-xylidino)-2-pyrimidinylthio]-acetic acid, a well-studied hepatocarcinogenic peroxisome proliferator. BrdU labeling was followed for the first 4 days of treatment during weeks 1, 2, and 4 with 0.1% of the peroxisome proliferator in the diet. This experimental design allowed the investigation of the immediate or early changes in cell proliferation taking place at the beginning of the treatment phase and under the steady-state condition of ensuing liver enlargement. More recently, proliferating cell nuclear antigen (PCNA) , an auxiliary protein of DNA polymerase 8 has been shown to be a highly stable protein found in all mammalian tissues and serves as endogenous replication marker (3, 4, 11, 14, 22, 51) . Because BrdU incorporation and PCNA expression constitute markers of DNA synthesis and indicators of cell proliferation, quantitative flow cytometry of these markers together with DNA distribution analysis were used to evaluate cell proliferation in a retrospective manner. Morphometric analysis of BrdU-labeled hepatocyte populations and nucleus and cell size parameters were used to corroborate the results of flow cytometric analysis. The findings suggest that an early wave of nuclear division occurs at the early stages of carcinogen administration without cumulative effects on cell proliferation.
MATERIALS AND METHODS

Animals and Treatment
Male Wistar [Crl:(WI)BR] rats, 47 days old, were obtained from Charles River Laboratories, Kingston, New York, and randomly assigned to a control group fed Purinao certified rodent chow, or to a treatment group fed 0.1°7o Wy-14,643 (purity ~~:98%, Chemsyn Science Laboratories, Lenexa, Kansas) in the same diet. On the first day of weeks 1, 2, and 4, rats were implanted subcutaneously with osmotic pumps (Alza, model 2ML1, flow rate 10 ~,1/hr) containing 5-bromo-2-deoxyuridine (Sigma, 50 mg/ml in 0.5 N NaHC03). The animals were sacrificed 4 days after implantation of pumps. The exposure level of Wy-14,643 employed in this study has been shown to cause liver tumors in rats over prolonged treatment. The animals sacrificed during weeks 1, 2, and 4 were exposed to Wy-14,643 for 4, 11, and 25 days, respectively. All procedures, maintenance, and treatment of the rats were in accordance with the principles of humane treatment as described by the National Institutes of Health's Guide for the Care and Use of Laboratory Animals (12) .
Flow Cytometric Evaluation of Cell Proliferation
Preparation of Liver Nuclei. Slices obtained from excised livers were quickly immersed in 4% buffered formalin and fixed for 24 hr, minced into approximately 1-mm~ pieces, and suspended in a wash solution containing 0.155 M phosphate-buffered saline (PBS), pH 7.4, and 2% fetal bovine serum. The suspension was then passed through a wire mesh (Shandon, Inc., Pittsburgh, Pennsylvania) and rinsed several times with the wash solution. The suspension containing nuclei was centrifuged at 300 X g for 5 min. The nuclear pellet was dispersed in [2] [3] [4] ml of cold 70% ethanol and stored at 4°C until processed for flow cytometric analysis (5) . BrdU Immunostaining of Liver Nuclei. The isolated nuclei were denatured in 1 ml of 1.5 M HCl for 20 min at room temperature, diluted by adding 15-fold volume of water, centrifuged at 300 X g for 5 min, and washed with 0.155 M PBS. BrdU incorporation in hepatocyte nuclei was detected by staining with 1:25 dilution of fluorescein isothiocyanate (FITC)-labeled anti-BrdU monoclonal antibodies (Boehringer Mannheim, Indianapolis, Indiana) for 30 min at 4°C. The proportion of cells in different phases of the cell cycle were determined using DNA stained with propidium iodide (PI) (50 [Lg/ml) in PBS for 30 min at 4°C and analyzed by flow cytometry. PCNA Immunostaining of Liver Nuclei. Ethanol-fixed isolated liver nuclei were washed and dispersed in PBS and stained with 1:25 dilution of anti-PCNA monoclonal antibodies (clone #19F4, Coulter Cytometry, Hialeah, Florida) in PBS for 15 min at room temperature and detected by staining with 1:100 dilution of FITC-conjugated goat anti-mouse immunoglobulins for 15 min at room temperature. DNA was stained with PI as already described.
Flow Cytometry. The distribution of fluorescence from nuclei was analyzed on an Epics Elite flow cytometer (Coulter Corporations, Hialeah, Florida) equipped with an air-cooled 15-mW argon laser adjusted to emit at 488 nm. Green FITC fluorescence was measured using a 550nm-long pass dichroic and a 525-nm bandpass filter. Red PI fluorescence was measured using a 625-nm long-pass dichroic and 575-nm bandpass filter. The analysis of each liver sample was carried out on 10,000-15,000 nuclei per sample. The fluorescence levels of isotype controls were subtracted from each sample to determine BrdU-positive and PCNA-positive nuclei. The flow cytometric data were analyzed using Multiplus cell cycle analysis software (Phoenix Flow Systems, San Diego, California).
Immunohistochemistry
BrdU Immunostaining. Liver slices were fixed in formalin for 24 hr, and paraffin sections were prepared and immunostained for BrdU (15) . Deparaffinized sections were denatured with 4 N HCl at 37°C for 20 min, neutralized by rinsing in PBS, and stained with anti-BrdU monoclonal antibodies (Beckton-Dickinson Co., Research Triangle Park, North Carolina) using Supersensitive kit (BioGenex Laboratories, Inc., San Ramon, California) and detected by developing alkaline phosphatase according to the manufacturer's instructions. Five to 10 randomly selected microscopic fields (using a X40 objective) per section were captured for subsequent analysis. The number of BrdU-labeled and nonlabeled hepatocytes per section was determined using Mocha for Windows (Jandel Software, San Rafael, California), after counting approximately 500 hepatocytes in each section. Labeling indices, expressed as a percentage of labeled nuclei versus total hepatocyte nuclei, were calculated for each animal. PCNA Immunostaining. Formalin-fixed, paraffin-embedded liver sections were stained for PCNA using an automated system (BioTek Solutions, Santa Barbara, California). All the reagents and antibodies were purchased commercially (BioTek Solutions). The sections were treated with an antigen retrieval solution by boiling in a microwave oven for 10 min. After rinsing with 0.4 M PBS, the sections were incubated with normal goat serum for 20 min and subsequently with antibody against PCNA (clone PC10) at room temperature for 25 min. The sections were then washed with PBS and incubated with biotinylated horse anti-mouse antibody (rat serum absorbed) for 25 min at room temperature, rinsed with PBS, and incubated with peroxidase-conjugated streptavidin for 30 min at room temperature. Final incubation with diaminobenzidine-H202 substrate was continued until visualization of the reaction product. After washing in water, slides were counterstained lightly with 10% hematoxylin, dehydrated in alcohol, cleared in xylene, and mounted with Permount (Sigma, St. Louis, Missouri).
Morphometric Analysis
A small piece of tissue was removed from the liver of each animal, immersed in a modified Kamovsky's fixative, minced into 1-mm3 blocks, fixed in 1 % osmium tetraoxide, dehydrated in graded ethanol solutions, and embedded in epon/araldite epoxy resin. Sections (1 (JLm thick) were cut from 5 randomly selected blocks per animal using a Reichert ultramicrotome with glass knifes and stained with Toluidine blue. These sections were examined by light microscopy to ensure adequate preparation and to verify the selection of medial lobular regions. From these sections, 4 were selected for morphometric analysis. Cellular parameters such as volume, diameter and number of nuclei, and cell and cytoplasmic volume were measured on 4 randomly selected fields per individual liver section, at a final magnification of Xl ,650, utilizing an image analysis system with a video overlay interfaced with the light microscope. Calibration was achieved using a reticle on the microscope stage.
Mitosis Counts
The number of hepatocytes in metaphase was counted in the same microscopic fields captured for the BrdUlabeling morphometric analysis as already described. The total number of interphase nuclei and those in metaphase were enumerated from approximately 500 hepatocytes in each section. Mitotic indices, expressed as a percentage of mitotic nuclei versus total hepatocyte nuclei, were calculated for each animal.
Biochemical Assays
Serum alkaline phosphatase (AP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), sorbitol dehydrogenase (SDH), and bilirubin were assayed on a Dacosg analyzer. Peroxisomal carnitine acetyltransferase (2) and cyanide-insensitive peroxisomal r3-oxidation (27) were assayed spectrophotometrically in crude peroxisomal fractions prepared from liver homogenate. Statistical Analysis Body weights, liver weights, and liver enzyme parameters were evaluated by pairwise comparisons made between each treatment group and controls using 2-tailed, 2-sample Student's t-test at the 1 % significance level separately for each timepoint. The cell-cycle parameters and labeling index were expressed as the number of labeled nuclei as a percentage of total hepatocyte nuclei counted by either flow cytometric or morphometric methods. Mean values were evaluated for statistical significance by 2-factor analysis of variance (ANOVA) evaluating treatment and time effects and by 2-tailed, 2-sample Student's t-test separately by timepoint at the 5% significance level.
RESULTS
Peroxisome Proliferator-Induced Changes
Sequential body weight and enzyme changes due to Wy-14,643 are summarized in Table I . Body weights decreased approximately 30% in the Wy-14,643 group over the course of treatment. Treated rats showed marked hepatomegaly with liver weight increases of approximately 50, 89, and 86% after 4, 11, and 25 days, respectively. Consistent with this hepatomegaly, Wy-14,643-treated rats exhibited multifocal hepatocellular hypertrophy and karyomegaly by routine microscopic analysis. These findings were consistent with previously published observations by several investigators.
Serum AST and ALT enzyme activities from treated rats increased with time over the 4-wk course of treat- ment. Serum AP levels decreased with age in both the control and Wy-14,643-treated group. However, by day 25, enzyme levels were significantly higher in the treatment group compared with controls. At the end of the study, serum AP, AST, and ALT increased in Wy-14,643treated rats by 1.7-, 4.2-, and 1.7-fold, respectively. No significant changes occurred in serum SDH and bilirubin. Peroxisomal (3-oxidation increased approximately 10-fold on day 4 of Wy-14,643 treatment and high levels of activity were sustained during the course of study. Carnitine acetyltransferase increased approximately 40-fold on day 4 and consistently high levels were observed during the remaining treatment period (Table I) . Fig. 1 (C&D) and anti-PCNA in Fig. 2 (C&D) . BrdU ( Table II ). The cell-cycle analysis based on PI-stained DNA showed increased cell numbers in S phase and G2-M on day 4 and essentially no differences at day 11 1 or 25 in controls. The number of BrdU-labeled nuclei in G2-M was increased 2-3-fold on day 11 and on day 25 in Wy-14,643-treated rats (Fig. 3) . PI-stained cells in Go G, phase were significantly reduced in Wy-14,643-treated groups (p < 0.05) on days 11 and 25, when compared to the corresponding controls. Also on day 11, cell populations in G2-M phase were significantly increased in treated rats (p < 0.005) than those from the corresponding control group. BrdU-labeled nuclei in G~-M phase were also significantly increased (p < 0.05) on day 11 1 and day 25. The cell population in G,-G, and S phase labeled with BrdU were not significantly different when compared to the corresponding controls at days 11 and 25 . Two-factor ANOVA analysis showed an overall decrease in the number of cells in G,-G, (p < 0.001) and an increase in S phase (p < 0.001) and G2-M phase (p < 0.005). A significant increase in BrdU-labeled cells (p < 0.005) was observed in Wy-14,643-treated groups due to increased BrdU-labeled nuclei in G2-M phase.
PCNA Expression in Proliferating Liver Cells. Similar to the temporal pattern of BrdU incorporation, significant increases in PCNA labeling were observed on day 4 in Wy-14,643-treated animals compared to controls (Table  TABLE II II), whereas no differences were found on days 11 and 25. The distribution of PCNA-positive nuclei in G2-M phase in the treated group was higher than controls on day 11 (Fig. 4 ), but the overall number of PCNA-positive nuclei was not significantly different (Table II) . PCNApositive nuclei, regardless of protein content, were also found in G, and G2-M in Wy-14,643-treated rats (Fig.   2C , D).
Immunohistochemical Staining of Proliferating Hepatocytes
Immunohistochemistry showed remarkable increases in BrdU-labeled nuclei in liver sections after 4 days of labeling. The populations of BrdU-labeled cells declined over the course of treatment. The labeling index was high, and approximately 80% of BrdU-labeled cells were in periportal areas (Fig. 5 ). Immunohistochemical localization of PCNA in hepato- cytes showed a marked increase in PCNA-expressing cells in the periportal region of the liver. Intense nuclear staining of PCNA was evident as an indicator of active DNA replication in S phase; a large number of hepatocytes also showed marked cytoplasmic staining (Fig. 5 ). Late G, cells showed light nuclear staining of PCNA, whereas cells in G2 had diffuse cytoplasmic staining (Fig. 5F) .
Hepatocellular Ploidy and Morphometric Analysis
Quantitation of BrdU-labeled cells by microscopic morphometry showed comparable results, as seen with flow cytometric bivariate analysis. The labeling indices of livers from Wy-14,643-treated rats were significantly higher after 4 days of treatment (Fig. 6A ). Approximately 60% of hepatocytes were BrdU-labeled during the 4-day labeling period. The labeling indices declined after 11 1 and 25 days of treatment and were not significantly different from controls.
The number of binucleated hepatocytes in Wy-14,643treated rats was not significantly different from control rats on days 4 and 11 and was significantly increased on day 25 compared to controls (Fig. 6B ). No significant changes were noted in mitotic indices of hepatocytes in Wy-14,643-treated rats compared to controls (Fig. 6C ).
Increases in the diameter of nuclei was noted upon morphometric analysis on days 11 and 25 of treatment (Fig.  7) . The size distribution of nuclei was unchanged between control and Wy-14,643-treated groups on day 4. A high percentage of cells with nuclear diameters greater than 9 u~m was found in Wy-14,643-treated livers on days 11 and 25 . As shown in Table III , mean nuclear diameters were significantly increased in the Wy-14,643treated groups at all timepoints, and the total number of nuclei per gram of liver remained unchanged. Increased number of hyperdiploid nuclei were noted (Fig. 7) .
DISCUSSION
Peroxisome proliferation is a recognized phenomenon concomitant with the induction of tumors in the liver of rodents. Peroxisome proliferators require continuous exposures to induce neoplastic growth, and oxidative damage can result from induction of catalase and other enzymes involved in peroxisomal fatty acid (3-oxidation (10, 37, 38) . Chemical carcinogens usually cause an increase in cell proliferation rates in the same organ that eventually presents with a tumor (30) (31) (32) . Cattley and Popp (8) suggested that carcinogenic peroxisome proliferators could promote the development of progressive lesions by the induction of cell proliferation in liver. Cell proliferation alone does not appear to constitute a determining process leading to tumors in most tissues (50) , and sustained cell replication may not be a primary feature of peroxisome proliferator-induced hepatocarcinogenesis (52) .
Results of this study are consistent with previous general observations on toxicological effects mediated by Wy-14,643 in rodents, including body weight gain suppression, liver changes, hepatocellular hypertrophy and karyomegaly, and increased peroxisomal enzyme activities. The changes observed in the populations of nuclei by flow cytometry represents DNA synthesis activity of the entire liver without differentiation of cell type and disposition within the liver lobule. Hepatic parenchymal cells contribute more than 90% of all DNA in intact nuclei obtained from the fractionation procedure (19) . The inclusion of nonparenchymal hepatic cell nuclei, representing no more than 10% of the total DNA, is not likely to influence the results as presented. Microscopic examination showed BrdU labeling only in periportal hepatocytes, whereas no significant labeling was observed in nonparenchymal cells, indicating that the replicative activity is confined to liver cells. Compared to autoradiograpic [3H]-thymidine incorporation and immunohistochemical detection of BrdU incorporation by light microscopy which show about 1 % labeling indices (16, 19, 31, 48) , the number of cells detected in the S phase by flow cytometry is significantly higher, due to the greater sensitivity of the fluorescence detection by laser cytometry and also due to the large number of cells that can be examined in a single sample. Reports based on the flow cytometric analyses of the DNA content have shown that 5-15% of cells are in the S phase in normal rat liver (19, 46, 47) . The high resolution of fluorescence detection allows distinction between cell populations in S phase and the G2-M phase based on minor DNA content changes in individual cells, and it is possible that some tetraploid and octaploid nuclei contribute cell counts in S phase. Based on the model used to fit Gj and G2 peaks as Gaussian curves and the S-phase distribution as a Gaussian-broadened distribution (13), S-phase cells constitute approximately 20-22% of the total population in control rat livers, a significantly higher number than reported earlier. The use of relatively young rats in the present study also might have led to high levels of S-phase nuclei in control rats. The acid-denaturation step in the preparation of nuclei for flow cytometry is an essential step for exposing BrdU, which may have contributed to widening of the resulting peaks. Such a step is not required for PI staining of DNA-based cytometric analysis. Nevertheless, this multivariate analysis describes the S-phase population dynamics most accurately, because of more homogeneous distribution of fluorescence (Figs. 1 and 2). BrdU labeling was significantly increased in Wy-14,643-treated rats after 4 days, as determined by flow cytometry and morphometry. The distribution of cells in various phases of the cell cycle was not significantly affected, with marginal changes on day 11 and day 25, when the cell populations shifted from resting phase to G2-M. The BrdU-positive cell population remained consistently high, approximately 2-fold, in G2-M phases in Wy-14,643-treated rats on days 11 and 25. These cellcycle data demonstrate that events relating to cell proliferation occur in the initial phase of the treatment, not followed by changes in the rate of DNA synthesis as the treatment progressed. Marsman et al (32) observed constant increases in DNA synthesis by [3H]-thymidine autoradiography with up to 1 yr of continuous administration of Wy-14,643, whereas the rate of DNA synthesis or the BrdU labeling index in this study declined in the first 4 wk of treatment. In the present study, the hepatocyte labeling index with BrdU as well as PCNA were significantly increased exclusively in the periportal region, and the decline observed by morphometry was similar to the decline in DNA labeling shown by flow cytometry. The increased percentage of cells appearing in G2-M phase and the analysis of liver nuclear profiles suggest that the progression of these additional cells (i.e., cells that are stimulated to enter the cell cycle by the test agent) through the cell cycle is arrested in the late stages of the cell cycle. Because there was no increase in the number of mitotic figures in the morphometric analysis of these samples, there is no evidence that the BrdUlabeled cells are actively dividing, though DNA synthesis proceeded. The morphometric and flow cytometric analyses support the observation that there was a shift from resting phase to G,-M phase (i.e., increased DNA content) together with increased nuclear size between days 11 and 25. Thus, it seems that a Gz block upon treatment with Wy-14,643 at the steady-state levels is possible.
The translocation of PCNA from cytoplasm to nucleus is markedly increased in proliferating cells as compared to quiescent elements (3) , and increased cytoplasmic PCNA may not be an exact indicator of cell proliferation (11) . PCNA expression has not been studied in detail during liver cell proliferation or in chemically induced cell replication. Wolf and Michalopoulos (51) showed that the BrdU incorporation and the PCNA labeling indices closely correlated with [3H]-thymidine incorporation after partial hepatectomy. Unlike BrdU labeling, which demonstrated DNA synthesis activity over the 4-day labeling period, the PCNA labeling index represents levels of the protein product at an interval posttreatment. PCNA expression in cells exposed to chemicals (4) or to Wy-14,643 may not provide true representation of S phase or proliferative activity because PCNAexpressing nuclei were also found in Go-Gl and G2-M phases. PCNA is constitutively expressed in S-phase-arrested cells as well as in transformed cells, such as in tumors (14, 22) . The synthesis or degradation of PCNA protein may be altered upon chemical treatment, resulting in the preservation of active or inactive protein in nuclei with DNA content relating to G, and G2 phases, particularly because no significant increases in the mitotic figures were observed in hepatocyte population of Wy-14,643-treated rats. In addition to this observation, the presence of PCNA in those hepatocytes other than in the S phase, as demonstrated by the cytoplasmic staining, was most likely caused by the activation of hepatocytes arrested in the G2 phase of the cell cycle that became activated by Wy-14,643 treatment, or by oxidative damage due to peroxisomes, or both.
In liver, most nongenotoxic carcinogens activate hepatocellular proliferation, many of them acting as direct liver mitogens inducing acute liver hyperplasia, although these agents are also mitotic inhibitors (9, 42) . Others induce liver cell death and provoke a regenerative response of the liver to compensate for the cell losses (20, 29) . In this context, chronic hepatic cell injury and regeneration has been closely associated with the induction of hepatic neoplasia in the absence of other carcinogenic stimuli (29) . Late-stage hepatocellular proliferation is observed in the case of peroxisome proliferators, including Wy-14,643, however, these cells are found in y-glutamyltranspeptidase-deficient foci, representing phenotypically different hepatocytes (36) . Marsman and Popp (31) further examined sequential continuity between highly proliferative basophilic lesions and hepatocellular tumors, emphasizing that the continuous chemical exposure was required for the progression of these lesions induced by Wy-14,643.
Polyploidy is found as a normal condition in a high proportion, particularly in liver (33, 43, 44) . Polyploidy is usually found in differentiated nondividing tissue, but these polyploid cells will divide under certain conditions such as regenerative growth (18) . In most instances, including in the case of peroxisome proliferators, the target molecules for the inducer ligands are non-DNA; hence, the importance of polyploidy as a genotoxic lesion remains uncertain. Despite the liver enlargement observed following Wy-14,643 administration, no evidence of mitotic activity was observed in treated livers, even though an increased number of cells were undergoing replicative DNA synthesis, as assessed by BrdU incorporation, and a remarkable shift occurred toward the tetraploid population. Mitotic figures did not appear to survive the treatment necessary for flow cytometric analysis. Bybee et al (7) previously reported increased mitotic activity of 1.3 and 6.8% in colchicine-arrested cells at 40 and 84 hr, respectively, after methyl clofenapate treatment in comparison to a much larger increase of 21.3% at 36 hr after partial hepatectomy. The increase in tetraploid populations could result from amitotic cytokinesis of the 2 X 2N binucleated cells following S phase (7, 43, 44) .
Wy-14,643 induces hepatocellular adenomas and carcinomas in the absence of an exogenous initiating stimulus (37, 39) , which cannot be attributed solely to the clonal expansion of spontaneously initiated cells. The absence of a genotoxic action of several peroxisome proliferators in the rat has been confirmed by measuring gross DNA degradation and unscheduled DNA synthesis as well as by measurement of single-strand breaks (35, 40) . Lefevre et al (28) observed a negative response with the peroxisome proliferator methyl clofenapate in the number of mutations in the liver from transgenic mice models of lac I (Big Blue) and lac Z (Muta mouse). Few laboratories have reported significant increases in the amount of 8-hydroxy-2'-deoxyguanosine, a specific marker of oxidative base damage, in the DNA from rat liver following long-term exposure to peroxisome proliferators (25, 41, 45) . Earlier studies have implicated acyl-CoA oxidase in the hepatocarcinogenesis induced by peroxisome proliferators (37, 39) . Enzymes of peroxisomal (3-oxidation system, including acyl-CoA oxidase, which generates H102, are transcriptionally activated by peroxisome proliferators via a receptor-mediated mechanism (23, 24, 38) . This hypothesis has been further confirmed by stably overexpressing the H202-generating acyl-CoA oxidase gene in CV-1 African green monkey kidney cells (10) . Transformed cells were capable of generating adenocarcinomas when transplanted in nude mice.
Comparative studies of mitogenic and hyperplastic responses upon treatment with these compounds are not available. It is reasonable to conclude that the massive hepatomegaly, associated with Wy-14,643 treatment, exerts a significant influence on the DNA synthesis. Although the initial wave of the DNA synthesis seems to be a characteristic feature of most nongenotoxic carcinogens upon short-term treatment, the magnitude of induction does not seem to be obligatory for all carcino-gens in general. The flow cytometric analysis of isolated nuclei from formalin-fixed samples and freshly isolated hepatocytes and potentially other useful markers would provide a useful tool for retrospective assessment of the cell proliferation in toxicologic pathology.
